{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:51:22Z","timestamp":1789415482563,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010347","name":"Fabrikant Einar Willumsens Mindelegat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009512","name":"Agnes og Poul Friis Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006088","name":"Direkt\u00f8r Emil C. Hertz og Hustru Inger Hertz Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008249","name":"Frimodt-Heineke Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007403","name":"Dagmar Marshalls Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007403","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011747","name":"Novo Nordisk Foundation Center for Basic Metabolic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2023.1219870","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T06:10:36Z","timestamp":1686204636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance"],"prefix":"10.3389","volume":"14","author":[{"given":"Morten Frier","family":"Gjerstorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00022.2019","article-title":"DNA Sensing in the innate immune response","volume":"35","author":"Briard","year":"2020","journal-title":"Physiol (Bethesda)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1314424","article-title":"Type-i-interferons in infection and cancer: unanticipated dynamics with therapeutic implications","volume":"6","author":"Musella","year":"2017","journal-title":"Oncoimmunology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.036","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"169","author":"Chiappinelli","year":"2017","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways","volume":"39","author":"Feng","year":"2020","journal-title":"EMBO J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215982","article-title":"DNA Methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1","volume":"552","author":"Traynor","year":"2023","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00615.x","article-title":"Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy","volume":"222","author":"Apte","year":"2008","journal-title":"Immunol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-dependent innate immune signaling by s-Phase-Specific DNA damage in breast cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.012","article-title":"DNA Damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity","volume":"42","author":"Hartlova","year":"2015","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.284","article-title":"Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression","volume":"176","author":"Bunt","year":"2006","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041037","article-title":"IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function","volume":"40","author":"Elkabets","year":"2010","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0578","article-title":"Mediators of inflammation-driven expansion, trafficking, and function of tumor-infiltrating MDSCs","volume":"7","author":"Tannenbaum","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.12.8200","article-title":"CD11b+\/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells","volume":"175","author":"Song","year":"2005","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2354","article-title":"Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression","volume":"67","author":"Bunt","year":"2007","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1610","article-title":"Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses","volume":"27","author":"Aggen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1823","article-title":"Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1beta, IL8, CXCL5, and mip-1alpha","volume":"23","author":"Najjar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29297","article-title":"Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients","volume":"136","author":"Jiang","year":"2015","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0373-7","article-title":"Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms","volume":"21","author":"Kim","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6305","article-title":"Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer","volume":"14","author":"Gonda","year":"2017","journal-title":"Oncol Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-1105","article-title":"Myeloid-derived suppressor cells and radiotherapy","volume":"10","author":"Jimenez-Cortegana","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2921","article-title":"Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer","volume":"75","author":"Takeuchi","year":"2015","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246153","article-title":"PDX models: a versatile tool for studying the role of myeloid-derived suppressor cells in breast cancer","volume":"14","author":"Gjerstorff","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100926","article-title":"Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages","volume":"187","author":"Novikov","year":"2011","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.12.002","article-title":"Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during mycobacterium tuberculosis infection","volume":"35","author":"Mayer-Barber","year":"2011","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1995.15.317","article-title":"Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist","volume":"15","author":"Huang","year":"1995","journal-title":"J Interferon Cytokine Res"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.150.10.4687","article-title":"Induction of circulating IL-1 receptor antagonist by IFN treatment","volume":"150","author":"Tilg","year":"1993","journal-title":"J Immunol"},{"key":"B36","article-title":"Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells","volume":"8","author":"Coclet-Ninin","year":"1997","journal-title":"Eur Cytokine Netw"},{"key":"B37","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/jir.1998.18.897","article-title":"Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-alpha2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8","volume":"18","author":"Reznikov","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1988.8.559","article-title":"Interleukin-1 can inhibit interferon-beta synthesis and its antiviral action: comparison with tumor necrosis factor","volume":"8","author":"Kohase","year":"1988","journal-title":"J Interferon Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.7.3959","article-title":"IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway","volume":"165","author":"Tian","year":"2000","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1219870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T06:10:42Z","timestamp":1686204642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1219870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2023.1219870"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1219870","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"article-number":"1219870"}}